Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLESSA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol is metabolized primarily via CYP3A4; desogestrel is converted to active metabolite etonogestrel via CYP2C9 and CYP2C19.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Desogestrel: 99.7% (SHBG); ethinyl estradiol: 98.5% (albumin, SHBG).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Desogestrel: 1.0-1.5 L/kg (extensive tissue distribution); ethinyl estradiol: 0.15-0.35 L/kg (limited).
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Desogestrel: 76% (oral); ethinyl estradiol: 55% (oral, variable due to first-pass metabolism).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (Cr Cl <30 m L/min); use with caution.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in Child-Pugh class C (severe hepatic impairment). For mild to moderate (Child-Pugh A or B), use with caution: reduce estrogen dose or discontinue if intolerance occurs.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche. For postmenarchal adolescents, dose same as adults: 0.15 mg desogestrel/0.02 mg ethinyl estradiol daily.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for postmenopausal women. No studies in geriatric population; use not recommended due to lack of benefit and increased thromboembolic risk with age.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptives. Risk increases with age and amount smoked (especially in women >35 years who smoke). Women should not use CYCLESSA if they smoke cigarettes and are over 35 years old.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism),Cerebrovascular disease,Cardiovascular disease including myocardial infarction,Liver disease including hepatic adenoma,Increased blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache,Bleeding irregularities
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Known or suspected pregnancy,Current or past breast cancer or other estrogen-sensitive cancer,Current or past deep vein thrombosis or pulmonary embolism,Current or history of thrombogenic valvular or rhythm disease,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Severe liver disease or liver tumor,Undiagnosed abnormal uterine bleeding,Age >35 years and smoking
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Alcohol does not affect efficacy but may increase risk of liver damage with high doses.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
First trimester: The use of combined hormonal contraceptives containing desogestrel and ethinyl estradiol is not associated with an increased risk of major birth defects. Discontinuation due to first-trimester exposure is not indicated. Second and third trimesters: Prolonged exposure to estrogen-progestin combinations has been associated with rare risks such as congenital heart defects and limb reduction defects in case-control studies, but absolute risk is low. Fetal risk from inadvertent use in pregnancy is minimal; termination not recommended.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. Studies with combined oral contraceptives suggest possible effects on milk production and composition; use during lactation should be postponed until the infant is weaned or at least 6 months postpartum. M/P ratio for ethinyl estradiol and desogestrel metabolites is not well established; limited data suggest low transfer.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dose adjustments are applicable as CYCLESSA is contraindicated during pregnancy. In the event of inadvertent use, the drug should be discontinued as soon as pregnancy is confirmed. No pharmacokinetic-based dose changes are required because use is not recommended in pregnancy.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
CYCLESSA (desogestrel/ethinyl estradiol) is a monophasic oral contraceptive. It may be used off-label for acne treatment. Breakthrough bleeding is common in the first 3 cycles. CYP3A4 inducers (e.g., rifampin) reduce efficacy; consider backup contraception.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet daily at the same time, even if no intercourse.,Start on the first day of menstrual period or first Sunday after period starts.,Use backup contraception for first 7 days if starting after day 5.,Missed pill: take as soon as remembered. If more than 2 missed, use backup method.,Vomiting or diarrhea may reduce effectiveness.,Report unexplained leg pain, chest pain, severe headache, or vision changes.,Smoking increases risk of serious cardiovascular side effects, especially if over 35.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLESSA vs ALYACEN 7/7/7, answered by our medical review team.
CYCLESSA is a Oral Contraceptive that works by Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLESSA and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLESSA is: One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLESSA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLESSA is classified as Category C. First trimester: The use of combined hormonal contraceptives containing desogestrel and ethinyl estradiol is not associated with an increased risk of major birth defects. Discontin. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.